Baird lowered the firm’s price target on Agenus to $6 from $8 and keeps an Outperform rating on the shares. The firm said they are encouraged by the recent financing and remain bullish on the differentiated profile for botensilimab and balstilimab in multiple tumor types, and look forward to multiple data catalysts next year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGEN: